Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04506554
Title A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center

bladder urothelial carcinoma

prostatic urethra urothelial carcinoma


Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.